Transcode Therapeutics (RNAZ) Common Equity (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Common Equity came in at $1.3 million in Q1 2026, down 87.84% YoY from $10.3 million in Q1 2025, and down 87.89% on a QoQ basis from $10.3 million in Q4 2025.
Transcode Therapeutics (RNAZ) Common Equity (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Common Equity data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Common Equity fell 87.84% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 87.84% YoY) and the FY2025 annual result came in at $10.3 million, up 611.98% from the prior year.
- Common Equity slipped to $1.3 million in Q1 2026, from $10.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $17.0 million in Q1 2022 to a low of -$2.0 million in Q4 2024.
- A 5-year average of $4.9 million and a median of $3.2 million in 2022 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 2036.0% in 2024, down 223.03% in 2024.
- Tracing RNAZ's Common Equity over 5 years: stood at $3.2 million in 2022, then plunged by 49.37% to $1.6 million in 2023, then slumped by 223.03% to -$2.0 million in 2024, then surged by 611.98% to $10.3 million in 2025, then slumped by 87.89% to $1.3 million in 2026.
- The last three Common Equity figures came in at $1.3 million (Q1 2026), $10.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 9.79 Bn |
| 10 | Transcode Therapeutics | 2.85 Mn | 2.85 Mn | - | -27.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | 10.34 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 10.29 Mn |
| Dec 31, 2024 | -2.02 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 4.58 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 4.44 Mn |
| Jun 30, 2023 | 2.09 Mn |
| Mar 31, 2023 | -236,792.00 |
| Dec 31, 2022 | 3.24 Mn |
| Sep 30, 2022 | 8.24 Mn |
| Jun 30, 2022 | 12.43 Mn |
| Mar 31, 2022 | 17.00 Mn |
| Dec 31, 2021 | 20.40 Mn |
| Sep 30, 2021 | 23.16 Mn |
| Jun 30, 2021 | -5.04 Mn |